Apalutamide with androgen deprivation therapy for treating prostate cancer: Appraisal consultation document

DRAFT guidance does not recommend apalutamide plus androgen deprivation therapy for treating prostate cancer in adults who have hormone-relapsed non-metastatic disease at high risk of metastasising or hormone-sensitive metastatic disease.

Source:

National Institute for Health Research